Subtopic Deep Dive
Medullary Thyroid Carcinoma Genetics
Research Guide
What is Medullary Thyroid Carcinoma Genetics?
Medullary Thyroid Carcinoma Genetics studies RET proto-oncogene mutations driving hereditary and sporadic MTC, including genotype-phenotype correlations in MEN2 syndromes.
Over 95% of hereditary MTC cases arise from germline RET mutations, with specific codons like M918T linked to MEN2B (Hofstra et al., 1994, 1151 citations). Familial MTC and MEN2A associate with mutations in codons 609, 611, 618, 620, and 634 (Mulligan et al., 1994, 651 citations). Genetic screening enables prophylactic thyroidectomy, achieving near 100% cure rates in early-detected cases (Kebebew et al., 2000, 670 citations).
Why It Matters
RET mutation testing identifies at-risk family members for prophylactic total thyroidectomy with central neck dissection, preventing MTC progression (Kebebew et al., 2000). Genotype-phenotype correlations guide surgical timing and extent, improving outcomes in MEN2A versus MEN2B (Mulligan et al., 1994; Hofstra et al., 1994). Population-based analyses confirm hereditary MTC's better prognosis with early genetic intervention (Roman et al., 2006). NCCN guidelines integrate RET testing for personalized MTC management (Haddad et al., 2022).
Key Research Challenges
Genotype-Phenotype Prediction
Correlating specific RET mutations with MTC aggressiveness and MEN2 penetrance remains imprecise despite known hotspots (Mulligan et al., 1994). Variability in age of onset and metastasis risk complicates prophylactic strategies (Hofstra et al., 1994). Advanced modeling of mutation effects on RET signaling is needed.
Sporadic MTC Detection
Somatic RET mutations occur in 25-50% of sporadic MTC, but routine screening lacks standardization (Kebebew et al., 2000). Distinguishing somatic from germline alterations requires tumor-normal sequencing (Roman et al., 2006). Cost-effective assays hinder widespread adoption.
Prophylactic Strategy Optimization
Timing and extent of thyroidectomy based on RET codon risk levels vary across guidelines (Perros et al., 2014). Long-term outcomes data for low-penetrance mutations remain sparse (Haddad et al., 2022). Balancing surgical risks against MTC prevention challenges clinical decisions.
Essential Papers
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum
Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent et al. · 2017 · Thyroid · 2.6K citations
Background: Thyroid disease in pregnancy is a common clinical problem. Since the guidelines for the management of these disorders by the American Thyroid Association (ATA) were first published in 2...
Thyroid cancer
Maria E. Cabanillas, David G. McFadden, Cosimo Durante · 2016 · The Lancet · 1.4K citations
Guidelines for the management of thyroid cancer
Petros Perros, Kristien Boelaert, Steve Colley et al. · 2014 · Clinical Endocrinology · 1.3K citations
In spite of advances in diagnostic methods, surgical techniques and clinical care, there are differences in survival of patients with thyroid cancer in different countries, and the outcome in the U...
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
Robert M.W. Hofstra, Rudy M. Landsvater, Isabella Ceccherini et al. · 1994 · Nature · 1.2K citations
Medullary thyroid carcinoma
Electron Kebebew, Philip H. G. Ituarte, Allan Siperstein et al. · 2000 · Cancer · 670 citations
Screening for MTC and early treatment (total thyroidectomy with central neck lymph node clearance) had nearly a 100% cure rate. Patients with postoperative hypercalcitoninemia without clinical or r...
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Lois M. Mulligan, Charis Eng, Catherine S. Healey et al. · 1994 · Nature Genetics · 651 citations
Prognosis of medullary thyroid carcinoma
Sanziana A. Roman, Rong Lin, Julie Ann Sosa · 2006 · Cancer · 535 citations
Abstract BACKGROUND. Medullary thyroid cancer (MTC) is a rare cancer. There is a relative paucity of data over the last decade with regard to the prognosis of these patients. Therefore, the authors...
Reading Guide
Foundational Papers
Start with Hofstra et al. (1994, 1151 citations) for RET M918T discovery in MEN2B, then Mulligan et al. (1994, 651 citations) for genotype-phenotype mappings, followed by Kebebew et al. (2000, 670 citations) for screening outcomes establishing genetic testing standards.
Recent Advances
Study Haddad et al. (2022, NCCN guidelines, 452 citations) for updated RET risk stratification; Perros et al. (2014, 1342 citations) for management protocols integrating genetics.
Core Methods
RET germline sequencing (exons 10-16); basal/stimulated calcitonin assays; genotype-specific risk levels (ATA categories: MOD, HIGH) guiding prophylactic thyroidectomy timing.
How PapersFlow Helps You Research Medullary Thyroid Carcinoma Genetics
Discover & Search
Research Agent uses searchPapers('RET M918T MEN2B') to retrieve Hofstra et al. (1994, 1151 citations), then citationGraph reveals 500+ citing works on RET mutations, while findSimilarPapers expands to genotype-phenotype studies like Mulligan et al. (1994). exaSearch queries 'RET codon 634 penetrance MTC' for latest screening protocols.
Analyze & Verify
Analysis Agent applies readPaperContent on Kebebew et al. (2000) to extract screening cure rates, verifyResponse with CoVe cross-checks RET mutation frequencies against Roman et al. (2006), and runPythonAnalysis parses genotype data for penetrance statistics with GRADE scoring for evidence strength in prophylactic efficacy.
Synthesize & Write
Synthesis Agent detects gaps in low-penetrance RET mutation outcomes via contradiction flagging across Perros et al. (2014) and Haddad et al. (2022), while Writing Agent uses latexEditText for RET signaling diagrams, latexSyncCitations to integrate 20+ references, and latexCompile for publication-ready reviews; exportMermaid generates mutation-phenotype flowcharts.
Use Cases
"Analyze RET mutation penetrance rates from population data in MTC families"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of Roman et al. 2006 cure rates and Kebebew et al. 2000 screening data) → statistical summary table with confidence intervals.
"Draft LaTeX review on RET genotype-phenotype correlations for MEN2"
Synthesis Agent → gap detection (Mulligan et al. 1994 vs recent NCCN) → Writing Agent → latexEditText (add codon table) → latexSyncCitations (Hofstra 1994 et al.) → latexCompile → PDF with RET mutation flowchart.
"Find open-source code for RET mutation variant effect prediction"
Research Agent → paperExtractUrls (Perros 2014 guidelines) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for codon risk scoring downloaded.
Automated Workflows
Deep Research workflow scans 50+ RET genetics papers via searchPapers → citationGraph → structured report on mutation hotspots (Hofstra/Mulligan 1994). DeepScan applies 7-step CoVe verification to prognosis claims from Roman et al. (2006) with GRADE grading. Theorizer generates hypotheses on undisclosed RET modifiers from gap detection across Kebebew (2000) and NCCN (2022).
Frequently Asked Questions
What defines Medullary Thyroid Carcinoma Genetics?
Focuses on RET proto-oncogene germline mutations causing 25% hereditary MTC, especially in MEN2A (codons 618-634) and MEN2B (M918T) (Hofstra et al., 1994; Mulligan et al., 1994).
What are key RET mutation testing methods?
Germline sequencing targets RET exons 10-11, 13-16; calcitonin screening precedes for families (Kebebew et al., 2000). Prophylactic thyroidectomy follows high-risk detection (Perros et al., 2014).
What are seminal papers on MTC genetics?
Hofstra et al. (1994, Nature, 1151 citations) identified M918T in MEN2B/sporadic MTC; Mulligan et al. (1994, Nature Genetics, 651 citations) linked specific codons to phenotypes.
What open problems exist in MTC genetics?
Unexplained phenotypic variability in identical RET mutations; somatic driver discovery beyond RET; optimized timing for low-risk codon carriers (Roman et al., 2006; Haddad et al., 2022).
Research Thyroid Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Medullary Thyroid Carcinoma Genetics with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.